This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779312

WORK PACKAGE 7

Methodological tools using multi-criteria value methods for HTA decision-making

Objectives
  • To create an analytical framework explaining the determinants of HTA coverage recommendations from a comparative perspective

  • To generate a predictive model, and test it empirically, analysing the relative importance of different value dimensions across countries implementing HTA and across different therapeutic areas

  • To develop (a) a multidimensional value framework and (b) preference elicitation techniques to inform HTA decision-making processes relating to the evaluation of new medicines;

  • To test the multi-dimensional value framework in practice and assess its suitability for evaluating new medicines with HTA agencies and relevant stakeholders

  • To research the practical implementation of MCDA evaluations, by adapting these in alignment with responsibilities and remits currently in place across different HTA bodies 

Methodology
  • Use an analytical framework to identify critical determinants in the evidence submitted to HTA bodies; develop a parsimonious model that captures these determinants in a systematic way and conduct econometric analysis to identify their relevance and importance in shaping HTA recommendations

  • Structure sound multi-criteria evaluation models using participatory Delphi processes to collect views from relevant stakeholders; develop methods within a socio-technical framework for the evaluation of new medicines based on a common and transparent value metric, using both qualitative (e.g. MACBETH) and quantitative (e.g. swing weighting) approaches

  • Test empirically the proposed value framework in collaboration with three HTA bodies using a rotational design, and develop an actionable model for the evaluation of medicines across different disease areas

  • Explore multi-criteria portfolio decision models to inform resource allocation and value based pricing indices obtained through multi-variate regression analyses using MCDA scores as tools to assist HTA bodies

Outcomes
  • An evidence-based and validated analytical framework outlining key critical determinants of HTA recommendations

  • A predictive model that includes parameter weights and their significance across settings and therapeutic areas

  • A (generic) multi-criteria model for the evaluation of new medicines as part of a common value framework

  • A series of empirical applications of the value framework, including transparent overall value rankings for the case of selected types of medicines following the elicitation of preferences from relevant experts and decision-makers

Research Update

January 2019 – IMPACT HTA 2nd Project Meeting (Presentation PDF)

Leads

Instituto Superior Técnico

 

London School of Economics and Political Science

Principal Investigators

Monica Oliveira

Panos Kanavos